Acasti Pharma: WuXi Clinical to conduct STRIVE-ON Phase 3 trial for GTX-104

Acasti Pharma announced WuXi Clinical Development, a wholly owned subsidiary of WuXi AppTec, will conduct Acasti’s STRIVE-ON Phase 3 safety trial for GTX-104. GTX-104 is Acasti’s novel, injectable nimodipine formulation for intravenous infusion that addresses high, unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. STRIVE-ON will evaluate GTX-104’s comparable safety and tolerability profile relative to oral nimodipine in patients hospitalized with aSAH.